Screener / SEC EDGAR /CIK 0001521036 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Diagnostics

Lantheus Holdings, Inc. LNTH

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. 10-K, Item 1

Employees
1,193
Headquarters
Bedford, MA
CEO
Mary Anne Heino
Next results
around Feb 25, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.5B through the costs to a net profit of $233.6M · income statement of the 10-K

20% operating margin
Revenue to Gross profit: $942.0MRevenue to Cost of revenue: $599.7MGross profit to Operating profit: $310.8MGross profit to Operating expenses: $631.1MOperating profit to Net profit: $233.6MOperating profit to Tax & other: $77.3MOperating expenses to R&D: $177.3MOperating expenses to Sales, admin & other: $453.8M Revenue: $1.5B REVENUE $1.5B +1% Y/Y Gross profit: $942.0M · 61% margin GROSS PROFIT $942.0M 61% margin · −5% Y/Y Cost of revenue: $599.7M · 39% of revenue COST OF REVENUE $599.7M 39% of revenue Operating profit: $310.8M · 20% margin OPERATING PROFIT $310.8M 20% margin · −32% Y/Y Operating expenses: $631.1M · 41% of revenue OPERATING EXPENSES $631.1M 41% of revenue Net profit: $233.6M · 15% margin NET PROFIT $233.6M 15% margin · −25% Y/Y Tax & other: $77.3M · 5% of revenue TAX & OTHER $77.3M 5% of revenue R&D: $177.3M · 12% of revenue R&D $177.3M 12% of revenue Sales, admin & other: $453.8M · 29% of revenue SALES, ADMIN & OTHER $453.8M 29% of revenue
Gross profit $942.0M 61% margin · −5% Y/Y
Operating profit $310.8M 20% margin · −32% Y/Y
Net profit $233.6M 15% margin · −25% Y/Y
The full income statement, year by year

LNTH among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 0.5%, above 13% of 154 peers (their median 10.5%) REVENUE GROWTH 0.5% · above 13% Gross margin: 61.3%, above 47% of 107 peers (their median 63.8%) GROSS MARGIN 61.3% · above 47% Operating margin: 18.6%, above 75% of 138 peers (their median 9.8%) OPERATING MARGIN 18.6% · above 75% Net margin: 17.3%, above 79% of 153 peers (their median 6.7%) NET MARGIN 17.3% · above 79% Return on capital: 12.0%, above 69% of 89 peers (their median 9.0%) RETURN ON CAPITAL 12.0% · above 69%
LNTH Peer median Below the median

What changed

37 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +11.6% ($321.3M to $358.6M) vs revenue +0.5% ($1.5B to $1.5B), +11.1 pts apart
  • Cash from operations $390.1M vs net income $233.6M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory -4.9% ($68.0M to $64.7M) vs revenue +0.5% ($1.5B to $1.5B), -5.4 pts apart
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

37 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 37 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    Following the expiration of regulatory exclusivity, we may face increased competition from generic products, including through abbreviated approval pathways under the Hatch‑Waxman Act or as a result of actions brought under the CREATES Act. The likelihood of entry or anticipated entry of such competing products cannot be predicted and…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    Our ability to grow Neuraceq is dependent on (A) our ability to engage our existing PYLARIFY customers to introduce Neuraceq to those customers, (B) expanded geographical access to Neuraceq, which in turn depends on our ability to increase Neuraceq manufacturing capacity at existing manufacturing sites and add additional sites, (C)…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    Ensuring adequate coding, coverage, and payment for Neuraceq is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using Neuraceq in PET/ CT imaging procedures. Neuraceq was approved by the…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    In addition, in order to remain competitive, in certain circumstances, we provide customers with rebates, which we estimate as a reduction to revenue at the time revenue is recognized. Judgment is required in making these estimates. These rebates can include performance-based offers that are based on attaining contractually specified…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$935.1M$1.3B$1.5B$1.5B
Net income$28.1M$326.7M$312.4M$233.6M
Operating cash flow$281.8M$305.3M$544.8M$390.1M
Free cash flow$21.8M$259.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.5B ▲ 0.5% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Lantheus Holdings, Inc., Bedford, MA · from the 10-K filed Feb 26, 2026

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases.

Headquarters
Bedford, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 1,193 employees, of which 1,056 were located in the United States and 137 were located internationally" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LNTH/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.